Official registry condition

Pancreatic Cancer peptide trials

4 selected ClinicalTrials.gov records carrying the official condition label Pancreatic Cancer. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.

Registry records

4 selected records.

Connected peptides

4 profiles.

Registry update years

2020–2026 in selected records.

Indication intelligence

Selected evidence landscape

Trial phases2

Phase labels copied from the retained ClinicalTrials.gov versions.

Registry statuses3

Overall statuses at each retained observation, not necessarily current today.

Across the connected peptide profiles, PeptideScanner also carries 113 selected PubMed records and 8 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Pancreatic Cancer unless their own cited source says so.

Collection change ledger

Recently changed records on this condition hub

All recent changes →

These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.

Record added

ClinicalTrials.gov record NCT03404661

PeptideScanner retained ClinicalTrials.gov record NCT03404661 at 2026-11-16T01:34:15.953Z. Its registry update date was 2023-06-06, and PeptideScanner's reviewed identity mapping was secretin.

PeptideScanner change date
November 16, 2026
Cited source date
June 6, 2023
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04543071

PeptideScanner retained ClinicalTrials.gov record NCT04543071 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-21, and PeptideScanner's reviewed identity mapping was motixafortide.

PeptideScanner change date
November 16, 2026
Cited source date
September 21, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01385956

PeptideScanner retained ClinicalTrials.gov record NCT01385956 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-09-28, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
September 28, 2020
Evidence lane
Clinical trials

Attributed registry records

Selected records

All trial facets →